$139.92 Share price 3.17% Change (1 day) 77.27% Change (1 year)💊 Pharmaceuticals🧬 BiotechCategoriesNovo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector ...
NOVO-NORDISK A-S-SPONS ADR live chart 106.382.256 % ↓ Swap Short: -3.1808 % Swap Long: -2.8597 % Sell 106.13 ↑ 25 Buy 106.38 ↑ Low: 104.42 Spread MT5 floating High: 108.58 Past performance is not a guarantee or prediction of future performance. ...
Latest Novo Nordisk A/S (NVON:MEX) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
Latest Novo Nordisk A/S (NOVO B:CPH) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.
Novo Nordisk (NVO) has a Smart Score of 8 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity.
NONOF Stock Price 1D 5D 1M 6M YTD 1Y 5Y 10Y MAX Basic Advanced -16.10% Novo Nordisk A/S price and volume Combination chart with 2 data series. Chart represents Novo Nordisk A/S price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart has 2 Y ...
Novo Nordisk A/S NVO reported second-quarter 2024 earnings of 65 cents per American Depositary Receipt (ADR), which missed the Zacks Consensus Estimate of 71 cents. The company had reported earnings of 63 cents per ADR in the
Novo Nordisk also agreed to acquire the asset Ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences PTE., Ltd. in 2023. The purchase price of the asset acquisition was USD 800 million with additional contingent payments of USD ...
Wegovy and another Novo Nordisk’s highly popular drug Ozempic have boosted the company’s earnings and stock price to make it the most valuable company in Europe last year. Ozempic, the diabetes drug, was approved in 2021 and saw sales in the greater China region double last year. As of ...
for $1.35 billion. The deal will give Novo Nordisk control over Emisphere's pill technology, which underpins its non-injectable type 2 diabetes treatment Rybelsus. Novo Nordisk will pay $7.82 per share, a 17% premium over the volume-weighted average share price for the five trading days ending...